Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study.

Jonathan CorrenChristopher S AmbroseJanet M GriffithsÅsa HellqvistAndrew W LindsleyJean-Pierre LlanosGene ColiceAndrew Menzies-Gow

Published in: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2022)

Tezepelumab was efficacious in patients with severe, uncontrolled asthma with evidence of allergic inflammation, defined by multiple clinically relevant definitions. These findings further support the benefits of tezepelumab in a broad population of patients with severe asthma, including those with severe allergic asthma.

Keyphrases

allergic rhinitis
chronic obstructive pulmonary disease
lung function
early onset
oxidative stress
drug induced
cystic fibrosis
atopic dermatitis